Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on June 21, 2021. The filing discloses the appointment of A. Ernest Toth, Jr. as Senior Vice President and Chief Financial Officer, effective June 15, 2021. Mr. Toth previously served as the Company's Interim Chief Financial Officer since December 2020.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the transition of A. Ernest Toth, Jr. from Interim Chief Financial Officer to a permanent executive role. No financial performance changes or operational shifts are detailed in this specific filing.
Compensation, Outlook, and Risks
The filing outlines the terms of Mr. Toth's Employment Agreement:
- Base Salary: $396,000 annually, subject to review.
- Equity Grant: An option to purchase 120,000 shares of common stock granted on June 15, 2021.
- Vesting Schedule: 25% on the first anniversary, 25% on the second anniversary, and 50% on the third anniversary.
- Annual Bonus: Target opportunity of 50% of the annual base salary.
- Severance Provisions: In the event of termination without Cause or for Good Reason, Mr. Toth is entitled to a pro-rata bonus, 12 months of monthly payments (salary + target bonus), continued health coverage, and accelerated vesting of equity awards due within the severance period. In the event of a Change in Control, severance payments are made as a lump sum.
The filing states there are no family relationships between Mr. Toth and other directors or officers, and no undisclosed transactions requiring Item 404(a) disclosure.
Key Facts for Investor Verification
- Confirmation of the effective date of the CFO appointment (June 15, 2021).
- Verification of the 120,000 share option grant and its specific vesting schedule.
- Review of the total potential compensation package, including the 50% target bonus and severance liabilities.
- Assessment of the Company's cash burn relative to the new executive compensation obligations, as financial metrics are not included in this filing.